Steven L Flamm

  • 11389 Citations
1994 …2022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Hepatic disease, Hepatitis B and C, Viral infections

Certifications and Licenses

Transplant Hepatology

Training Experience

1992Residency, Beth Israel Deaconess Medical Center, Boston
1993Fellowship, Beth Israel Deaconess Medical Center, Boston
1996Fellowship, Beth Israel Deaconess Medical Center, Boston

Education/Academic qualification

MD, University of Pennsylvania

… → 1989

Research interests

  • Esophagogastroduodenoscopy (EGD)
  • Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Liver Biopsy
  • Liver Transplant
  • Liver/Hepatic Disease
  • Variceal Banding
  • Viral Hepatitis

Fingerprint Dive into the research topics where Steven L Flamm is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Hepacivirus Medicine & Life Sciences
Chronic Hepatitis C Medicine & Life Sciences
Ribavirin Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences
Genotype Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Hepatitis C Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2002 2022

Research Output 1994 2019

10 Citations (Scopus)

AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis

American Gastroenterological Association Institute Clinical Guidelines Committee, Feb 2019, In : Gastroenterology. 156, 3, p. 748-764 17 p.

Research output: Contribution to journalArticle

Ulcerative Colitis
Practice Guidelines

Changing demographics among populations prescribed HCV treatment, 2013-2017

Tsai, N., Bacon, B., Curry, M., Flamm, S. L., Milligan, S., Wick, N., Younossi, Z. & Afdhal, N., Jul 1 2019, In : American Journal of Managed Care. 25, 7, p. 319-323 5 p.

Research output: Contribution to journalArticle

3 Citations (Scopus)

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Flamm, S., Reddy, K. R., Zadeikis, N., Hassanein, T., Bacon, B. R., Maieron, A., Zeuzem, S., Bourliere, M., Calleja, J. L., Kosloski, M. P., Oberoi, R. K., Lin, C. W., Yu, Y., Lovell, S., Semizarov, D. & Mensa, F. J., Feb 2019, In : Clinical Gastroenterology and Hepatology. 17, 3, p. 527-535.e6

Research output: Contribution to journalArticle

Proton Pump Inhibitors
Reducing Agents
Chronic Hepatitis C
Virus Diseases
4 Citations (Scopus)

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Flamm, S., Mutimer, D., Asatryan, A., Wang, S., Rockstroh, J., Horsmans, Y., Kwo, P. Y., Weiland, O., Villa, E., Heo, J., Gane, E., Ryder, S. D., Welzel, T. M., Ruane, P. J., Agarwal, K., Ng, T. I., Xue, Z., Lovell, S. S., Krishnan, P., Kopecky-Bromberg, S. & 3 others, Trinh, R., Mensa, F. J. & Wyles, D. L., Mar 2019, In : Journal of Viral Hepatitis. 26, 3, p. 337-349 13 p.

Research output: Contribution to journalArticle

Chronic Hepatitis C

Hepatobiliary Complications in Critically Ill Patients

Cheung, A. & Flamm, S., May 2019, In : Clinics in liver disease. 23, 2, p. 221-232 12 p.

Research output: Contribution to journalReview article

Critical Illness
Wounds and Injuries
Bile Acids and Salts
Systemic Inflammatory Response Syndrome